Clinical course of atrial fibrillation in older adults: The importance of cardiovascular events beyond stroke

European Heart Journal

Volumn 35, Issue 4, 2014, Pages 250-256

  Piccini, Jonathan P ^a,b   Hammill, Bradley G ^a   Sinner, Moritz F ^c   Hernandez, Adrian F ^a,b   Walkey, Allan J ^d   Benjamin, Emelia J ^d,e   Curtis, Lesley H ^a,b   Heckbert, Susan R ^f  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BOSTON UNIVERSITY   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Atrial fibrillation; Heart failure; Mortality; Outcome assessment (health care)

Indexed keywords

AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; COMORBIDITY; DISEASE COURSE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICARE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; VERY ELDERLY;

ATRIAL FIBRILLATION; HEART FAILURE; MORTALITY; OUTCOME ASSESSMENT (HEALTH CARE);

AGED; ATRIAL FIBRILLATION; EMERGENCY SERVICE, HOSPITAL; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HOSPITALIZATION; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE; UNITED STATES;

EID: 84893108089     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht483     Document Type: Article

References (18)

1. Piccini JP, Hammill BG, Sinner MF, Jensen PN, Hernandez AF, Heckbert SR, Benjamin EJ, Curtis LH. Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007. Circ Cardiovasc Qual Outcomes 2012;5:85-93.
2. Stewart S, Hart CL, Hole DJ, McMurray JJ.Apopulation-based study of the long-Term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002;113:359-364.
3. Institute of Medicine. Initial National Priorities for Comparative Effectiveness Research. Washington, DC: National Academies Press; 2009. http://www.nap.edu/ openbook.php?record-id=12648 (8 August 2012)
4. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-1139.
5. Birman-Deych E, Waterman AD, YanY, Nilasena DS, Radford MJ, Gage BF. Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. Med Care 2005;43:480-485.
6. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on Atrial Fibrillation. Chest 2010; 137:263-272.
7. Gage BF, Waterman AD, ShannonW, Boechler M, RichMW, Radford MJ. Validation of clinical classification schemes for predicting stroke: Results from the national registry of atrial fibrillation. JAMA 2001;285:2864-2870.
8. Gajewski J, Singer RB. Mortality in an insured population with atrial fibrillation. JAMA 1981;245:1540-1544.
9. Wann LS, Curtis AB, January CT, Ellenbogen KA, Lowe JE, Estes NA 3rd, Page RL, Ezekowitz MD, Slotwiner DJ, Jackman WM, Stevenson WG, Tracy CM; 2011 Writing Group Members, Fuster V, Rydén LE, Cannom DS, Le Heuzey JY, Crijns HJ, Lowe JE, Curtis AB, Olsson S, Ellenbogen KA, Prystowsky EN, Halperin JL, Tamargo JL, Kay GN, Wann L; 2006 Writing Committee Members, Jacobs AK, Anderson JL, Albert N, Hochman JS, Buller CE, Kushner FG, Creager MA, Ohman EM, Ettinger SM, Stevenson WG, Guyton RA, Tarkington LG, Halperin JL, Yancy CW; ACCF/AHA Task Force Members. 2011 ACCF/AHA/HRS focused update on themanagement of patients with atrial fibrillation (updating the 2006 guideline): A report of theAmericanCollegeofCardiology Foundation/AmericanHeart Association Task Force on Practice Guidelines. Circulation 2011;123:104-123.
10. Alonso A, Agarwal SK, Soliman EZ, Ambrose M, Chamberlain AM, Prineas RJ, Folsom AR. Incidence of atrial fibrillation in whites and African-Americans: The Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 2009; 158:111-117.
11. Torp-Pedersen C, Møller M, Bloch-Thomsen PE, Køber L, Sandøe E, Egstrup K, Agner E, Carlsen J, Videbaek J, Marchant B, Camm AJ. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med 1999;341:857-865.
12. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, D'Agostino RB, Murabito JM, Kannel WB, Benjamin EJ. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: The Framingham Heart Study. Circulation 2003;107:2920-2925.
13. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 1998; 98:946-952.
14. Miyasaka Y, Barnes ME, Bailey KR, Cha SS, Gersh BJ, Seward JB, Tsang TS. Mortality trends in patients diagnosed with first atrial fibrillation: A 21-year community-based study. J Am Coll Cardiol 2007;49:986-992.
15. Walkey AJ, WienerRS, Ghobrial JM, Curtis LH, Benjamin EJ. Incident strokeand mortality associated with new-onset atrial fibrillation in patients hospitalized with severe sepsis. JAMA 2011;306:2248-2254.
16. Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray JJ, Puu M, Yusuf S, PfefferMA;CHARMInvestigators. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: Results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 2006;47:1997-2004.
17. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest 2010;138:1093-1100.
18. Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, Eikelboom J, Brueckmann M, Yusuf S, Connolly SJ. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation 2012;125: 669-676.